Rapamycins: Mechanism of action and cellular resistance

Shile Huang, Mary Ann Bjornsti, Peter J Houghton

Research output: Contribution to journalReview article

264 Citations (Scopus)

Abstract

Rapamycins are macrocyclic lactones that possess immunosuppressive, antifungal and antitumor properties. The parent compound, rapamycin, is approved as an immunosuppressive agent for preventing rejection in patients receiving organ transplantation. Two analogues, CCI-779 and RAD001 are currently being investigated as anticancer agents. Rapamycins first bind a cyclophilin FKBP12, and this complex binds and inhibits the function of mTOR (mammalian target of rapamycin) a serine/threonine (Ser/Thr) kinase with homology to phosphatidylinositol 3′ kinase. Currently, as mTOR is the only identified target, this places rapamycins in a unique position of being the most selective kinase inhibitor known. Consequently these agents have been powerful tools in elucidating the role of mTOR in cellular growth, proliferation, survival and tumorigenesis. Increasing evidence suggests that mTOR acts as a central controller sensing cellular environment (nutritional status or mitogenic stimulation) and regulating translation initiation through the eukaryotic initiation factor 4E, and ribosomal p70 S6 kinase pathways. Here we review the conserved TOR signaling pathways, conceptual basis for tumor selectivity, and the mechanisms of resistance to this class of antitumor agent.

Original languageEnglish (US)
Pages (from-to)222-232
Number of pages11
JournalCancer Biology and Therapy
Volume2
Issue number3
DOIs
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Sirolimus
Immunosuppressive Agents
Antineoplastic Agents
Tacrolimus Binding Protein 1A
Eukaryotic Initiation Factor-4E
Phosphatidylinositol 3-Kinase
Cyclophilins
70-kDa Ribosomal Protein S6 Kinases
Protein-Serine-Threonine Kinases
Organ Transplantation
Lactones
Nutritional Status
Carcinogenesis
Phosphotransferases
Cell Proliferation
Survival
Growth

Keywords

  • Cancer
  • Rapamycins
  • Resistance
  • Ribosomal biogenesis
  • Therapy
  • Translation initiation
  • Yeast

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Rapamycins : Mechanism of action and cellular resistance. / Huang, Shile; Bjornsti, Mary Ann; Houghton, Peter J.

In: Cancer Biology and Therapy, Vol. 2, No. 3, 01.05.2003, p. 222-232.

Research output: Contribution to journalReview article

Huang, Shile ; Bjornsti, Mary Ann ; Houghton, Peter J. / Rapamycins : Mechanism of action and cellular resistance. In: Cancer Biology and Therapy. 2003 ; Vol. 2, No. 3. pp. 222-232.
@article{c600caf0be074bde843c4ba3e3cb1d90,
title = "Rapamycins: Mechanism of action and cellular resistance",
abstract = "Rapamycins are macrocyclic lactones that possess immunosuppressive, antifungal and antitumor properties. The parent compound, rapamycin, is approved as an immunosuppressive agent for preventing rejection in patients receiving organ transplantation. Two analogues, CCI-779 and RAD001 are currently being investigated as anticancer agents. Rapamycins first bind a cyclophilin FKBP12, and this complex binds and inhibits the function of mTOR (mammalian target of rapamycin) a serine/threonine (Ser/Thr) kinase with homology to phosphatidylinositol 3′ kinase. Currently, as mTOR is the only identified target, this places rapamycins in a unique position of being the most selective kinase inhibitor known. Consequently these agents have been powerful tools in elucidating the role of mTOR in cellular growth, proliferation, survival and tumorigenesis. Increasing evidence suggests that mTOR acts as a central controller sensing cellular environment (nutritional status or mitogenic stimulation) and regulating translation initiation through the eukaryotic initiation factor 4E, and ribosomal p70 S6 kinase pathways. Here we review the conserved TOR signaling pathways, conceptual basis for tumor selectivity, and the mechanisms of resistance to this class of antitumor agent.",
keywords = "Cancer, Rapamycins, Resistance, Ribosomal biogenesis, Therapy, Translation initiation, Yeast",
author = "Shile Huang and Bjornsti, {Mary Ann} and Houghton, {Peter J}",
year = "2003",
month = "5",
day = "1",
doi = "10.4161/cbt.2.3.360",
language = "English (US)",
volume = "2",
pages = "222--232",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - Rapamycins

T2 - Mechanism of action and cellular resistance

AU - Huang, Shile

AU - Bjornsti, Mary Ann

AU - Houghton, Peter J

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Rapamycins are macrocyclic lactones that possess immunosuppressive, antifungal and antitumor properties. The parent compound, rapamycin, is approved as an immunosuppressive agent for preventing rejection in patients receiving organ transplantation. Two analogues, CCI-779 and RAD001 are currently being investigated as anticancer agents. Rapamycins first bind a cyclophilin FKBP12, and this complex binds and inhibits the function of mTOR (mammalian target of rapamycin) a serine/threonine (Ser/Thr) kinase with homology to phosphatidylinositol 3′ kinase. Currently, as mTOR is the only identified target, this places rapamycins in a unique position of being the most selective kinase inhibitor known. Consequently these agents have been powerful tools in elucidating the role of mTOR in cellular growth, proliferation, survival and tumorigenesis. Increasing evidence suggests that mTOR acts as a central controller sensing cellular environment (nutritional status or mitogenic stimulation) and regulating translation initiation through the eukaryotic initiation factor 4E, and ribosomal p70 S6 kinase pathways. Here we review the conserved TOR signaling pathways, conceptual basis for tumor selectivity, and the mechanisms of resistance to this class of antitumor agent.

AB - Rapamycins are macrocyclic lactones that possess immunosuppressive, antifungal and antitumor properties. The parent compound, rapamycin, is approved as an immunosuppressive agent for preventing rejection in patients receiving organ transplantation. Two analogues, CCI-779 and RAD001 are currently being investigated as anticancer agents. Rapamycins first bind a cyclophilin FKBP12, and this complex binds and inhibits the function of mTOR (mammalian target of rapamycin) a serine/threonine (Ser/Thr) kinase with homology to phosphatidylinositol 3′ kinase. Currently, as mTOR is the only identified target, this places rapamycins in a unique position of being the most selective kinase inhibitor known. Consequently these agents have been powerful tools in elucidating the role of mTOR in cellular growth, proliferation, survival and tumorigenesis. Increasing evidence suggests that mTOR acts as a central controller sensing cellular environment (nutritional status or mitogenic stimulation) and regulating translation initiation through the eukaryotic initiation factor 4E, and ribosomal p70 S6 kinase pathways. Here we review the conserved TOR signaling pathways, conceptual basis for tumor selectivity, and the mechanisms of resistance to this class of antitumor agent.

KW - Cancer

KW - Rapamycins

KW - Resistance

KW - Ribosomal biogenesis

KW - Therapy

KW - Translation initiation

KW - Yeast

UR - http://www.scopus.com/inward/record.url?scp=0346362997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346362997&partnerID=8YFLogxK

U2 - 10.4161/cbt.2.3.360

DO - 10.4161/cbt.2.3.360

M3 - Review article

C2 - 12878853

AN - SCOPUS:0346362997

VL - 2

SP - 222

EP - 232

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 3

ER -